Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-010905
Filing Date
2017-05-15
Accepted
2017-05-15 09:12:00
Documents
58
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ogxi-10q_20170331.htm 10-Q 1287438
2 EX-2.1 ogxi-ex21_418.htm EX-2.1 18574
3 EX-31.1 ogxi-ex311_7.htm EX-31.1 9040
4 EX-31.2 ogxi-ex312_8.htm EX-31.2 9027
5 EX-32.1 ogxi-ex321_10.htm EX-32.1 4826
6 EX-32.2 ogxi-ex322_6.htm EX-32.2 4799
  Complete submission text file 0001564590-17-010905.txt   5067141

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT ogxi-20170331.xml EX-101.INS 1024100
8 XBRL TAXONOMY EXTENSION SCHEMA ogxi-20170331.xsd EX-101.SCH 43643
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ogxi-20170331_cal.xml EX-101.CAL 38873
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ogxi-20170331_def.xml EX-101.DEF 148459
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE ogxi-20170331_lab.xml EX-101.LAB 340972
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ogxi-20170331_pre.xml EX-101.PRE 260503
Mailing Address 19820 NORTH CREEK PARKWAY SUITE 201 BOTHELL WA 98011
Business Address 19820 NORTH CREEK PARKWAY SUITE 201 BOTHELL WA 98011 425-686-1500
ONCOGENEX PHARMACEUTICALS, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 17841528
SIC: 2835 In Vitro & In Vivo Diagnostic Substances